Revvity Pharmaceutical Import Profile — Finland (DGFT 2022–2026)

Name: Revvity Pharmaceutical Import Records from India — 4 Products, $423.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Revvity — Pharmaceutical Importer Profile (2026) | 4 Products, $423.6K Trade | TransData Nexus

Revvity

Pharmaceutical Importer · Finland · Medical Devices & Diagnostics Focus · $423.6K Total Trade · DGFT Verified

Revvity is a pharmaceutical importer based in Finland with a total trade value of $423.6K across 4 products in 3 therapeutic categories. Based on 9 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Revvity sources from 1 verified Indian supplier, with Advy Chemical Private Limited accounting for 100.0% of imports.

Revvity — Import Portfolio & Supplier Network

Revvity import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Revvity?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Advy Chemical Private Limited	$116.0K	3	100.0%

Revvity sources from 1 verified Indian supplier across 3 distinct formulations. The sourcing is highly concentrated — Advy Chemical Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Revvity Import?

Formulation	Value	Ships
Diagnostic reagents - pregnancy associated plasma protein a (papp-a	$50.0K	1
Diagnostic reagents pregnancy associated plasma protein a (papp-a)	$50.0K	1
Pregnancy associated plasma protein a(papp - a)	$16.0K	1

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Protein	Nutritional Supplements	$150.0K	3	1.0%	8
2	Diagnostic	Medical Devices & Diagnostics	$100.0K	2	0.5%	11
3	Reagent	Medical Devices & Diagnostics	$100.0K	2	0.8%	8
4	Plasma	Other	$73.6K	2	2.6%	6

Revvity imports 4 pharmaceutical products across 3 categories into Finland totaling $423.6K.

Revvity — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Revvity is a Finnish pharmaceutical importer and buyer specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Headquartered in Finland, Revvity plays a pivotal role in the country's pharmaceutical distribution network, ensuring the availability of essential medicinal products to meet domestic healthcare needs. The company operates as a primary wholesaler, sourcing a diverse range of pharmaceutical products from international suppliers to cater to the Finnish market.

2Distribution Network

While specific details about Revvity's warehouse locations and logistics capabilities are not publicly disclosed, the company is known to maintain a robust distribution network within Finland. This network is designed to ensure efficient delivery of pharmaceutical products across the country, meeting the demands of various healthcare facilities and pharmacies. Revvity's strategic partnerships with international suppliers, including those in India, further enhance its ability to source and distribute a wide array of pharmaceutical products.

3Industry Role

In Finland's pharmaceutical supply chain, Revvity functions primarily as a wholesaler, importing finished pharmaceutical formulations from international markets, notably India. By sourcing a diverse range of products, Revvity ensures a steady supply of essential medicines to the Finnish market, thereby supporting the healthcare system's needs. The company's role is crucial in bridging the gap between international pharmaceutical manufacturers and the domestic market, facilitating access to a broad spectrum of medicinal products.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Revvity

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Revvity's sourcing strategy exhibits a high degree of concentration, with a total import value of $424,000 USD from India across nine shipments, encompassing four products across three therapeutic categories. The top five products imported include Protein ($150K), Diagnostic ($100K), Reagent ($100K), and Plasma ($74K), with the top three categories being Medical Devices & Diagnostics (47.2%), Nutritional Supplements (35.4%), and Other (17.4%). This concentration indicates a strategic focus on specific product categories and suppliers, which can offer benefits such as streamlined procurement processes and potentially better pricing.

However, this single-source dependency also presents risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or supplier-specific challenges. The absence of alternative suppliers in Revvity's sourcing profile suggests a need for diversification to mitigate potential risks. The stability of the relationship with the sole Indian supplier, ADVY Chemical Private Limited, is critical. The fact that all shipments are sourced from this single supplier underscores the importance of maintaining a strong and reliable partnership to ensure uninterrupted supply.

2Supply Chain Resilience

Revvity's supply chain resilience is currently limited due to its reliance on a single supplier for all imports from India. This lack of diversification makes the supply chain vulnerable to disruptions from various factors, including geopolitical tensions, regulatory changes, or operational issues within the supplier's facilities. The absence of backup suppliers and limited formulation diversity further exacerbate this vulnerability. To enhance resilience, Revvity could consider establishing relationships with additional suppliers and diversifying the range of formulations imported, thereby reducing dependency on a single source and mitigating potential risks.

Importing Pharmaceuticals into Finland — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Finland

1Regulatory Authority & Framework

In Finland, the Finnish Medicines Agency (Fimea) serves as the national competent authority responsible for regulating pharmaceuticals. Operating under the Ministry of Social Affairs and Health, Fimea oversees the manufacture, import, distribution, marketing, and dispensing of medicinal products to ensure public health and safety. Fimea's regulatory framework encompasses the Medicines Act (395/1987) and the Medicines Decree, which set forth the requirements for marketing authorizations, import licenses, and the supervision of pharmaceutical activities. These regulations are designed to maintain the quality, safety, and efficacy of medicinal products available in Finland. (suomi.fi)

2Import Licensing & GMP

Import licensing in Finland is governed by Fimea, which requires that all medicinal products imported into the country possess a valid marketing authorization or registration. This ensures that imported products meet the necessary standards for quality, safety, and efficacy. Good Manufacturing Practice (GMP) certification is a critical component of this process. Fimea recognizes GMP certificates from the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers like Revvity must ensure that their suppliers hold valid GMP certifications from these recognized bodies to comply with Finnish regulations. (suomi.fi)

Revvity — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Revvity's product strategy focuses on importing finished pharmaceutical formulations across three therapeutic categories: Medical Devices & Diagnostics (47.2%), Nutritional Supplements (35.4%), and Other (17.4%). This strategic focus aligns with market demand in Finland, where there is a significant need for diagnostic tools and nutritional supplements to support healthcare services. The importation of products such as Protein, Diagnostic, Reagent, and Plasma indicates a commitment to providing essential medical supplies that address critical health concerns. By concentrating on these categories, Revvity aims to meet the specific needs of the Finnish healthcare system and contribute to improved patient outcomes.

2Sourcing Profile

Revvity's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a particular emphasis on products in the Medical Devices & Diagnostics and Nutritional Supplements categories. This focus suggests a strategic decision to leverage India's manufacturing capabilities and cost advantages in these product segments. The reliance on a single supplier, ADVY Chemical Private Limited, indicates a preference for streamlined procurement processes and potentially stronger supplier relationships. However, this approach also highlights the need for diversification to mitigate risks associated with supply chain disruptions.

Market Positioning

Seller's Guide — How to Become a Supplier to Revvity

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Revvity's supply chain, especially if they can offer competitive pricing, reliable delivery schedules, and high-quality products. Diversifying Revvity's supplier base could lead to a more robust and flexible supply chain, benefiting both Revvity and its suppliers. Additionally, expanding the range of formulations imported could help Revvity better meet the evolving needs of the Finnish healthcare market.

2Requirements & Qualifications

Indian exporters seeking to supply Revvity and the Finnish market must ensure that their products have valid marketing authorizations or registrations in Finland. Compliance with Good Manufacturing Practice (GMP) standards recognized by Fimea, such as EU GMP, WHO GMP, or PIC/S, is mandatory. Additionally, products must meet Finnish labeling requirements, including instructions in Finnish and Swedish, and adhere to serialization mandates for traceability. Ensuring these certifications and quality standards will facilitate entry into the Finnish pharmaceutical market.

3How to Approach

Frequently Asked Questions — Revvity

What products does Revvity import from India?

Revvity imports 4 pharmaceutical products across 3 categories. Top imports: Protein ($150.0K), Diagnostic ($100.0K), Reagent ($100.0K), Plasma ($73.6K).

Who supplies pharmaceuticals to Revvity from India?

Revvity sources from 1 verified Indian suppliers. The primary supplier is Advy Chemical Private Limited (100.0% of imports, $116.0K).

What is Revvity's total pharmaceutical import value?

Revvity's total pharmaceutical import value from India is $423.6K, based on 9 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Revvity focus on?

Revvity imports across 3 categories. The largest: Medical Devices & Diagnostics (47.2%), Nutritional Supplements (35.4%), Other (17.4%).

Get Full Revvity Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.